Moreover, TRPML1 activated the BDNF/TrkB signaling pathway and interacted with the p62-dependent dynein to attenuate NAD in AD (Figure 7), providing new insights into understanding pathology and potential therapeutic targets for AD. This evidence concerns the gene SQSTM1 and Alzheimer disease.